Short Communications
Chenxue Mao, Juan Chen, Ting Zou, Yuankang Zhou, Junyan Liu, Xi Li, Xiangping Li, Min Li, Pinhua Pan, Wei Zhuo, Yang Gao, Shuo Hu, Desheng Xiao, Lin Wu, Zhan Wang, Heng Xu, Wen Yang, Yingjie Xu, Haihua Xiao, Kazuhiko Hanada, Wei Zhang, Honghao Zhou, Jiye Yin, Zhaoqian Liu. Genome-wide analysis identify novel germline genetic variations in ADCY1 influencing platinum-based chemotherapy response in non-small cell lung cancer[J]. Acta Pharmaceutica Sinica B, 2022, 12(3): 1514-1522

Genome-wide analysis identify novel germline genetic variations in ADCY1 influencing platinum-based chemotherapy response in non-small cell lung cancer
Chenxue Maoa,b, Juan Chena,b, Ting Zoua,b, Yuankang Zhoua,b, Junyan Liua,b, Xi Lia,b, Xiangping Lia, Min Lic, Pinhua Panc, Wei Zhuoa,b, Yang Gaod, Shuo Hue, Desheng Xiaof, Lin Wug, Zhan Wangh, Heng Xui, Wen Yangj, Yingjie Xuj, Haihua Xiaok, Kazuhiko Hanadal, Wei Zhanga,b, Honghao Zhoua,b, Jiye Yina,b, Zhaoqian Liua,b
a. Departments of Clinical Pharmacology and Pharmacy, Hunan Key Laboratory of Pharmacogenetics, and National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha 410008, China;
b. Institute of Clinical Pharmacology, Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, Central South University, Changsha 410078, China;
c. Department of Respiratory, Xiangya Hospital, Central South University, Changsha 410008, China;
d. Department of Thoracic Surgery, Xiangya Hospital, Central South University, Changsha 410008, China;
e. Department of Nuclear Medicine, Xiangya Hospital, Central South University, Changsha 410008, China;
f. Department of Pathology, Xiangya Hospital, Central South University, Changsha 410008, China;
g. Department of Thoracic Medicine, Hunan Cancer Hospital, Changsha 410014, China;
h. Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital, Changsha 410014, China;
i. State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center of Biotherapy, Chengdu 610000, China;
j. Department of Molecular and Cellular Biochemistry, School of Medicine, Shanghai Jiaotong University, Shanghai 200025, China;
k. Beijing National Laboratory for Molecular Sciences, State Key Laboratory of Polymer Physics and Chemistry, Institute of Chemistry, Chinese Academy of Sciences, Beijing 100190, China;
l. Department of Pharmacometrics and Pharmacokinetics Meiji Pharmaceutical University, Tokyo 204-8588, Japan
Abstract:
To explore the pharmacogenomic markers that affect the platinum-based chemotherapy response in non-small-cell lung carcinoma (NSCLC), we performed a two-cohort of genome-wide association studies (GWAS), including 34 for WES-based and 433 for microarray-based analyses, as well as two independent validation cohorts. After integrating the results of two studies, the genetic variations related to the platinum-based chemotherapy response were further determined by fine-mapping in 838 samples, and their potential functional impact were investigated by eQTL analysis and in vitro cell experiments. We found that a total of 68 variations were significant at P < 1×10-3 in cohort 1 discovery stage, of which 3 SNPs were verified in 262 independent samples. A total of 541 SNPs were significant at P < 1×10-4 in cohort 2 discovery stage, of which 8 SNPs were verified in 347 independent samples. Comparing the validated SNPs in two GWAS, ADCY1 gene was verified in both independent studies. The results of fine-mapping showed that the G allele carriers of ADCY1 rs2280496 and C allele carriers of rs189178649 were more likely to be resistant to platinum-based chemotherapy. In conclusion, our study found that rs2280496 and rs189178649 in ADCY1 gene were associated the sensitivity of platinum-based chemotherapy in NSCLC patients.
Key words:    Pharmacogenomics    NSCLC    Platinum    GWAS    WES    ADCY1    Precious medicine    SNPs   
Received: 2021-06-20     Revised: 2021-09-02
DOI: 10.1016/j.apsb.2021.10.007
Funds: This work was supported by the National Key Research and Development Programs (2016YFC1306900 and 2017ZX09304-014, China), National Natural Science Foundation of China (81573508, 81874327, 81773823, 81803640 and 82073943, China), Fundamental Research Funds for the Central Universities of Central South University (2018zzts251, China), The Strategy-Oriented Special Project of Central South University in China (ZLXD2017003), Youth Science Foundation of Xiangya Hospital, Central South University (2017Q02, China) and Hunan Cancer Hospital Climb Plan (YF2020011, China).
Corresponding author: Jiye Yin,E-mai:yinjiye@csu.edu.cn;Zhaoqian Liu,E-mai:zqliu@csu.edu.cn     Email:yinjiye@csu.edu.cn;zqliu@csu.edu.cn
Author description:
Service
PDF(KB) Free
Print
0
Authors
Chenxue Mao
Juan Chen
Ting Zou
Yuankang Zhou
Junyan Liu
Xi Li
Xiangping Li
Min Li
Pinhua Pan
Wei Zhuo
Yang Gao
Shuo Hu
Desheng Xiao
Lin Wu
Zhan Wang
Heng Xu
Wen Yang
Yingjie Xu
Haihua Xiao
Kazuhiko Hanada
Wei Zhang
Honghao Zhou
Jiye Yin
Zhaoqian Liu

References:
[1] Rottenberg S, Disler C, Perego P. The rediscovery of platinum-based cancer therapy. Nat Rev Cancer 2021; 21: 37-50
[2] Johnstone TC, Suntharalingam K, Lippard SJ. The next generation of platinum drugs: targeted Pt(II) agents, nanoparticle delivery, and Pt(IV) prodrugs. Chem Rev 2016; 116: 3436-3486
[3] Drogemoller BI, Wright GEB, Lo C, Le T, Brooks B, Bhavsar AP, et al. Pharmacogenomics of cisplatin-induced ototoxicity: successes, shortcomings, and future avenues of research. Clin Pharmacol Ther 2019; 106: 350-359
[4] Lee JW, Pussegoda K, Rassekh SR, Monzon JG, Liu G, Hwang S, et al. Clinical practice recommendations for the management and prevention of cisplatin-induced hearing loss using pharmacogenetic markers. Ther Drug Monit 2016; 38: 423-431
[5] Xu H, Robinson GW, Huang J, Lim JY, Zhang H, Bass JK, et al. Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss. Nat Genet 2015; 47: 263-266
[6] Wheeler HE, Gamazon ER, Frisina RD, Perez-Cervantes C, El Charif O, Mapes B, et al. Variants in WFS1 and other mendelian deafness genes are associated with cisplatin-associated ototoxicity. Clin Cancer Res 2017; 23: 3325-3333
[7] Yin JY, Shen J, Dong ZZ, Huang Q, Zhong MZ, Feng DY, et al. Effect of eIF3a on response of lung cancer patients to platinum-based chemotherapy by regulating DNA repair. Clin Cancer Res 2011; 17: 4600-4609
[8] Yin JY, Li X, Li XP, Xiao L, Zheng W, Chen J, et al. Prediction models for platinum-based chemotherapy response and toxicity in advanced NSCLC patients. Cancer Lett 2016; 377: 65-73
[9] Yin JY, Huang Q, Zhao YC, Zhou HH, Liu ZQ. Meta-analysis on pharmacogenetics of platinum-based chemotherapy in non small cell lung cancer (NSCLC) patients. PLoS One 2012; 7: e38150
[10] Chen J, Wang Z, Zou T, Cui J, Yin J, Zheng W, et al. Pharmacogenomics of platinum-based chemotherapy response in NSCLC: a genotyping study and a pooled analysis. Oncotarget 2016; 7: 55741-55756
[11] Wu C, Xu B, Yuan P, Ott J, Guan Y, Liu Y, et al. Genome-wide examination of genetic variants associated with response to platinum-based chemotherapy in patients with small-cell lung cancer. Pharmacogenet Genomics 2010; 20: 389-395
[12] Wu X, Ye Y, Rosell R, Amos CI, Stewart DJ, Hildebrandt MA, et al. Genome-wide association study of survival in non-small cell lung cancer patients receiving platinum-based chemotherapy. J Natl Cancer Inst 2011; 103: 817-825
[13] Sato Y, Yamamoto N, Kunitoh H, Ohe Y, Minami H, Laird NM, et al. Genome-wide association study on overall survival of advanced non-small cell lung cancer patients treated with carboplatin and paclitaxel. J Thorac Oncol 2011; 6: 132-138
[14] Hu L, Wu C, Zhao X, Heist R, Su L, Zhao Y, et al. Genome-wide association study of prognosis in advanced non-small cell lung cancer patients receiving platinum-based chemotherapy. Clin Cancer Res 2012; 18: 5507-5514
[15] Han JY, Lee YS, Shin ES, Hwang JA, Nam S, Hong SH, et al. A genome-wide association study of survival in small-cell lung cancer patients treated with irinotecan plus cisplatin chemotherapy. Pharmacogenomics J 2014; 14: 20-27
[16] Li X, Huang K, Zhang Q, Zhou J, Sun H, Tang F, et al. Genome-wide association study identifies four SNPs associated with response to platinum-based neoadjuvant chemotherapy for cervical cancer. Sci Rep 2017; 7: 41103
[17] Galvan-Femenia I, Guindo M, Duran X, Calabuig-Farinas S, Mercader JM, Ramirez JL, et al. Genomic profiling in advanced stage non-small-cell lung cancer patients with platinum-based chemotherapy identifies germline variants with prognostic value in SMYD2. Cancer Treat Res Commun 2018; 15: 21-31
[18] Goffin J, Lacchetti C, Ellis PM, Ung YC, Evans WK. First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer: a systematic review. J Thorac Oncol 2010; 5: 260-274
[19] Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92-98
[20] Howie BN, Donnelly P, Marchini J. A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. PLoS Genet 2009; 5: e1000529
[21] Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 2006; 38: 904-909
[22] Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81: 559-575
[23] Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263-265
[24] Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, et al. The structure of haplotype blocks in the human genome. Science 2002; 296: 2225-2229
[25] Pruim RJ, Welch RP, Sanna S, Teslovich TM, Chines PS, Gliedt TP, et al. LocusZoom: regional visualization of genome-wide association scan results. Bioinformatics 2010; 26: 2336-2337
[26] Khrunin AV, Khokhrin DV, Moisseev AA, Gorbunova VA, Limborska SA. Pharmacogenomic assessment of cisplatin-based chemotherapy outcomes in ovarian cancer. Pharmacogenomics 2014; 15: 329-337
[27] Hung YC, Huang GS, Lin LW, Hong MY, Se PS. Thea sinensis melanin prevents cisplatin-induced nephrotoxicity in mice. Food Chem Toxicol 2007; 45: 1123-1130
[28] Yang SK, Hong M, Baek J, Choi H, Zhao W, Jung Y, et al. A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia. Nat Genet 2014; 46: 1017-1020
[29] Yin JY, Li X, Zhou HH, Liu ZQ. Pharmacogenomics of platinum-based chemotherapy sensitivity in NSCLC: toward precision medicine. Pharmacogenomics 2016; 17: 1365-1378
[30] Zou T, Liu J, She L, Chen J, Zhu T, Yin J, et al. A perspective profile of ADCY1 in cAMP signaling with drug-resistance in lung cancer. J Cancer 2019; 10: 6848-6857
Similar articles: